Modern Anti-Tuberculosis Drugs and Their Classification. Part I: First-Line Drugs
作者： L. A. Kayukova , E. A. Berikova
DOI: 10.1007/S11094-020-02239-2
关键词: Tb control 、 Effective treatment 、 Anti tuberculosis 、 Tuberculosis 、 Chemistry 、 Pharmacology toxicology 、 First line 、 Pharmacy 、 Internal medicine
摘要: The historical classification (1993) of anti-tuberculosis drugs included three (I-III) lines that were subdivided into five groups (2006). duration treatment drug-sensitive (DS) tuberculosis (TB) with first-line is 6 – 12 months; multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) second-line drugs, 18 months longer. Directly Observed Treatment Short course (DOTS) DOTS-Plus therapies are measures world control. Based on the need for more effective MDR XDR TB, 2016 introduced six (A-C D1-D3) in connection development new anti-TB drugs. present review presents preparations their derivatives possessing activity against DS (DR) M. strains.
springer.com
sci-hub.st 参考文章(51)
Brendan Prideaux, Laura E Via, Matthew D Zimmerman, Seokyong Eum, Jansy Sarathy, Paul O'Brien, Chao Chen, Firat Kaya, Danielle M Weiner, Pei-Yu Chen, Taeksun Song, Myungsun Lee, Tae Sun Shim, Jeong Su Cho, Wooshik Kim, Sang Nae Cho, Kenneth N Olivier, Clifton E Barry, Véronique Dartois, The association between sterilizing activity and drug distribution into tuberculosis lesions Nature Medicine. ,vol. 21, pp. 1223- 1227 ,(2015) , 10.1038/NM.3937
Holger Schünemann, Dennis Falzon, Ernesto Jaramillo, The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis European Respiratory Journal. ,vol. 38, pp. 393- ,(2011)
Kelly E. Dooley, Patrick Sayre, Julie Borland, Elizabeth Purdy, Shuguang Chen, Ivy Song, Amanda Peppercorn, Stephanie Everts, Stephen Piscitelli, Charles Flexner, Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. Journal of Acquired Immune Deficiency Syndromes. ,vol. 62, pp. 21- 27 ,(2013) , 10.1097/QAI.0B013E318276CDA9
H. S. Naveen Kumar, Thaigarajan Parumasivam, Fatimah Jumaat, Pazilah Ibrahim, Mohd. Zaini Asmawi, Amirin Sadikun, Synthesis and evaluation of isonicotinoyl hydrazone derivatives as antimycobacterial and anticancer agents Medicinal Chemistry Research. ,vol. 23, pp. 269- 279 ,(2014) , 10.1007/S00044-013-0632-2
Kyung-Wook Jo, Wonjun Ji, Yoonki Hong, Sang-Do Lee, Woo Sung Kim, Dong Soon Kim, Tae Sun Shim, The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis Respiratory Medicine. ,vol. 107, pp. 292- 297 ,(2013) , 10.1016/J.RMED.2012.10.021
Hassan Safi, Subramanya Lingaraju, Anita Amin, Soyeon Kim, Marcus Jones, Michael Holmes, Michael McNeil, Scott N Peterson, Delphi Chatterjee, Robert Fleischmann, David Alland, Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β- D -arabinose biosynthetic and utilization pathway genes Nature Genetics. ,vol. 45, pp. 1190- 1197 ,(2013) , 10.1038/NG.2743
Marieli O. Rodrigues, Jéssica B. Cantos, Caroline R. Montes D’Oca, Karina L. Soares, Tatiane S. Coelho, Luciana A. Piovesan, Dennis Russowsky, Pedro A. da Silva, Marcelo G. Montes D’Oca, Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids. Bioorganic & Medicinal Chemistry. ,vol. 21, pp. 6910- 6914 ,(2013) , 10.1016/J.BMC.2013.09.034
Catherine Vilchèze, William R. Jacobs JR., Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities Microbiology spectrum. ,vol. 2, pp. 431- 453 ,(2014) , 10.1128/MICROBIOLSPEC.MGM2-0014-2013
R. Bayer, D. Wilkinson, R. Bayer, Directly observed therapy for tuberculosis: history of an idea. The Lancet. ,vol. 345, pp. 1545- 1548 ,(1995) , 10.1016/S0140-6736(95)91090-5
Oluseye K. Onajole, Patrick Govender, Paul D. van Helden, Hendrik G. Kruger, Glenn E.M. Maguire, Ian Wiid, Thavendran Govender, Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. European Journal of Medicinal Chemistry. ,vol. 45, pp. 2075- 2079 ,(2010) , 10.1016/J.EJMECH.2010.01.046